Bridging the Gap to Reach Treatment Goals in DLBCL
This activity is supported by an educational grant from Kite, a Gilead Company.
CE Activity Release Date: March 15, 2023
CE Activity Expiration Date: February 28, 2024
Time to Complete activity: 1 hour
ACTIVITY DESCRIPTION
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, which typically occurs in patients over the age of 60 years. While chemoimmunotherapy (R-CHOP) has been considered the first line treatment option, approximately 40% of patient with DLBCL will fail to respond and experience a relapse. Autologous hematopoietic stem cell transplantation (AHCT) has been used as treatment for patients who experience a relapse; however, many patients are ineligible for the procedure due to age, comorbidities, or resistance to second-line chemoimmunotherapy. Novel treatment options have thus been introduced to the treatment landscape of DLBCL, including chimeric antigen receptor T-cell therapy (CAR T) with trial results displaying sustained remissions for relapsed patients. Because the options for treatment of DLBCL have changed rapidly, it is important for treating physicians to be aware of the options that are available as well as assist them in overcoming barriers that may impact their treatment.
Join us for this educational Med Table Talk® LIVE on Bridging the Gap to Reach Treatment Goals in DLBCL as our experts have a candid conversation about the available treatment options for DLBCL, how cellular therapists and community physicians must communicate to ensure adequate care between referring and treating physicians, and how to recognize and address common treatment barriers.
This taped satellite symposium was derived from the 2023 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCTTM and CIBMTR® on February 18, 2023.
TARGET AUDIENCE
This activity is intended for hematologic oncology clinicians (physicians, physician associates, nurses, pharmacists) who provide care for individuals with aggressive B-cell lymphomas who may be candidates for cellular therapy.
SPEAKERS
Christopher R. Flowers, MD, MS, FASCO
Division Head ad Interim, Division of Cancer Medicine
Chair, Professor, Department of Lymphoma/Myeloma
John M O’Quinn Endowed Chair in Cancer Research
MD Anderson Cancer Center
Houston, TX
Sergio A. Giralt, MD, FACP
Melvin Berlin Family Chair in Myeloma Research
Professor of Medicine
Weill Cornell Medical College
Deputy Head, Division of Hematologic Malignancies
Attending Physician, Adult BMT Service
Memorial Sloan Kettering Cancer Center
New York, NY
Sanjay K. Juneja, MD
Hematologist & Medical Oncologist
Chief of Oncology
Baton Rouge General Hospital
Mary Bird Perkins Cancer Center
Baton Rouge, LA
Sanjay Sharma, MD
St. Jude Crosson Cancer Institute
Providence OC Cancer Institute
Fullerton, CA
Rayne H. Rouce, MD, BS
Associate Professor
Department of Pediatrics
Texas Children’s Cancer Center for Cell and Gene Therapy
Baylor College of Medicine
Houston, TX
EDUCATIONAL OBJECTIVES
After completing this CE activity, the participant should be better able to:
- Assess the efficacy and safety of current and emerging therapeutic options for the treatment of R/R DLBCL
- Evaluate the potential use of a bridging therapies in patients with R/R DLBCL if the therapy goal is CAR T or stem cell treatment
- Plan strategies to overcome barriers in accessing care and involvement in clinical trials for patients with DLBCL
AGENDA
- Welcome
- Evaluate the latest standard of care for treating patients with DLBCL across various therapy lines
- Analyze how eligibility criteria for CAR T and ASCT inform treatment decision-making throughout the disease course
- Communicate available non-CAR T treatment regimens for patients who are ineligible for CAR T-cell therapy or ASCT
- Implement strategies to dissolve issues related to access to therapy and clinical trials
- Recap of key points
ACCREDITATION, SUPPORT AND CREDIT
Continuing Medical and Professional Education: 2023 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR are sponsored by the Medical College of Wisconsin.
ACCME ACCREDITATION STATEMENT
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.
AMA CREDIT DESIGNATION
The Medical College of Wisconsin designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc., and the Medical College of Wisconsin. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSING CONTINUING PROFESSIONAL DEVELOPMENT
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 0.75 contact hour in the area of pharmacology.
CONTINUING PHARMACY EDUCATION
Medical Learning Institute, Inc. designates this enduring continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-020-H01-P
Type of Activity: Knowledge
AAPA CREDIT DESIGNATION STATEMENT
Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until February 28, 2024. PAs should only claim credit commensurate with the extent of their participation.
SUPPORT STATEMENT
This activity is supported by an educational grant from Kite, a Gilead Company.
DISCLOSURE & CONFLICT OF INTEREST POLICY
Medical Learning Institute, Inc. and the Medical College of Wisconsin are committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
FACULTY DISCLOSURES
Planner/Presenter
Christopher R. Flowers, MD, MS, FASCO
Division Head ad Interim, Division of Cancer Medicine
Chair, Professor, Department of Lymphoma/Myeloma
John M O’Quinn Endowed Chair in Cancer Research
MD Anderson Cancer Center
Houston, TX
Christopher R. Flowers, MD, MS, FASCO has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: AbbVie, AstraZeneca, Bayer, BeiGene, Bio Ascend, Bristol Myers Squibb, Celgene, Denovo Biopharma, Foresight Diagnostics, Genentech/Roche, Genmab, Gilead, Karyopharm, N Power, Pharmacyclics/Janssen, Seagen, Spectrum
Speakers’ Bureau: AbbVie, AstraZeneca, Bayer, BeiGene, Bio Ascend, Bristol Myers Squibb, Celgene, Denovo Biopharma, Foresight Diagnostics, Genentech/Roche, Genmab, Gilead, Karyopharm, Pharmacyclics/Janssen, Seagen, Spectrum
Research Grant: 4D, AbbVie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Celgene, Cellectis, EMD Serono, Genentech/Roche, Gilead, Guardant, Iovance, Janssen Pharmaceutical, Kite, Morphosys, Nektar, Novartis, Pfizer, Pharmacyclics, Sanofi
Stock Ownership: Foresight Diagnostics, N Power
Planner/Presenter
Sergio A. Giralt, MD, FACP
Melvin Berlin Family Chair in Myeloma Research
Professor of Medicine
Weill Cornell Medical College
Deputy Head, Division of Hematologic Malignancies
Attending Physician, Adult BMT Service
Memorial Sloan Kettering Cancer Center
New York, NY
Sergio A. Giralt, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: Actinium Pharmaceuticals, Inc., Amgen Inc., Bristol Myers Squibb, Celgene Corp., Janssen Pharmaceuticals, Omeros Corporation, Pfizer Inc., Sanofi, Takeda Pharmaceutical Co.
Research Grant: Actinium Pharmaceuticals, Inc, Amgen Inc., Bristol Myers Squibb, Celgene Corp., GlaxoSmithKline, Jazz Pharmaceuticals, Inc., Janssen Pharmaceuticals, Omeros Corporation, Pfizer Inc., Sanofi
Planner/Presenter
Sanjay K. Juneja, MD
Hematologist & Medical Oncologist
Chief of Oncology
Baton Rouge General Hospital
Mary Bird Perkins Cancer Center
Baton Rouge, LA
Sanjay K. Juneja, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: Daiichi Sankyo, Guardant 360
Speakers’ Bureau: AstraZeneca Pharmaceuticals, Daiichi Sankyo, Guardant 360, Merck & Co., Inc., Tempus
Stock Ownership: Phenomune, xCures
Independent Contractor: xCures
Planner/Presenter
Sanjay Sharma, MD
St. Jude Crosson Cancer Institute
Providence OC Cancer Institute
Fullerton, CA
Sanjay Sharma, MD has a financial interest/relationship or affiliation in the form of:
Speakers’ Bureau: Amgen, AstraZeneca, Bristol Myers Squibb, Guardant, Merck, Regeneron
Presenter
Rayne H. Rouce, MD, BS
Associate Professor
Department of Pediatrics
Texas Children’s Cancer Center for Cell and Gene Therapy
Baylor College of Medicine
Houston, TX
Rayne H. Rouce, MD, BS, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: Novartis Pharmaceuticals Corporation, Pfizer Inc.
Research Grant: Tessa Therapeutics
All of the relevant financial relationships of individuals for this activity have been mitigated.
PLANNING COMMITTEE AND CONTENT/PEER REVIEWERS
The planners and content/peer reviewers from Medical Learning Institute, Inc. and the Medical College of Wisconsin, the accredited providers, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute, Inc.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact Mary Vu via email at mvu@mlieducation.org.
For Pharmacists, MLI will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.
ABOUT THIS ACTIVITY
Medical Learning Institute, Inc. and the Medical College of Wisconsin are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical College of Wisconsin and Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.
